CDA | Evidence Driven
CDA | Evidence Driven

olopatadine hydrochloride and mometasone

Details

Generic Name:
olopatadine hydrochloride and mometasone
Project Status:
Pending
Therapeutic Area:
Seasonal allergic rhinitis
Manufacturer:
Bausch Health
Call for patient/clinician input open:
Brand Name:
Ryaltris
Project Line:
Reimbursement Review
Project Number:
SR0848-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) is indicated for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : May 10, 2024